Modified · Programs in Clinical Development

Clinical Program | Phase 2 | Phase 3 | RegulatoryReview(h) | 2026 Events to Date | Select UpcomingMilestones Ophthalmology EYLEA HD (aflibercept) 8 mg(a) | –Pre-filled syringe (U.S.) –RVO (Japan) | –Approved by European Commission ("EC") for RVO –Approved by U.S. Food and Drug Administration ("FDA") for extension of dosing intervals up to 20 weeks in wAMD and DME | –FDA decisions for pre-filled syringe Cemdisiran(k) (siRNARNAi therapeutic targeting C5) ± pozelimab(f) (antibody to C5) | –Geographic atrophy | –Report initial results from lead-in cohort of Phase 3 study in geographic atrophy (combination and cemdisiran monotherapy) (fourth quarter 2026) Immunology & Inflammation Dupixent (dupilumab)(b)Antibody to IL-4R alpha subunit | –Asthma in pediatrics (2–5 years of age) –Chronic pruritus of unknown origin ("CPUO") –Lichen simplex chronicus | –CSU in pediatrics (2–11 years of age) (Japan) –Bullous pemphigoid (EU) | –Approved by FDA for AFRS –Approved by FDA and EC for CSU in pediatrics –Approved by Japan's Ministry of Health, Labour and Welfare ("MHLW") for bullous pemphigoid | –EC decision on regulatory submissionWithdrew regulatory application in EU for bullous pemphigoid (second half 2026) –Report results from Phase 3 studystudies in lichen simplex chronicus (second half 2026)did not meet primary endpoints Kevzara (sarilumab)(b)Antibody to IL-6R | –Systemic juvenile idiopathic arthritis ("sJIA") (pivotal study) Itepekimab(b)Bremzalerbart-atisnolerbart (REGN3500REGN5713-5715)Antibody to IL-33 | –Chronic rhinosinusitis without nasal polyposis ("CRSsNP") | –COPD(e) –CRSwNP REGN5713-5715Multi-antibody Multi-antibody therapy to Bet v 1 | –Birch allergy | –Initiated second Phase 3 trial in birch allergy REGN1908-1909(f)Multi-antibody therapy to Fel d 1 | –Cat allergy | –Initiate second Phase 3 study in cat allergy (second half 2026)